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Abstract 
Background: Factor XIII (F XIII) is an essential parameter for final clot stability. The 
purpose of this study was to determine the impact of the addition of F XIII on clot stability as 
assessed by Rotation Thromboelastometry (ROTEM®). 
Methods: In 90 intensive care patients ROTEM® measurements were performed after in vitro 
addition of F XIII 0.32 IU, 0.63 IU, 1.25 IU and compared to diluent controls (DC; aqua 
injectabile) resulting in approximate F XIII concentrations of 150, 300 and 600%. Baseline 
measurements without any additions were also performed. The following ROTEM® 
parameters were measured in FIBTEM and EXTEM tests: clotting time (CT), clot formation 
time (CFT), maximum clot firmness (MCF), maximum lysis (ML), maximum clot elasticity 
(MCE) and α-angle (αA). Additionally, laboratory values for F XIII, fibrinogen (FBG), 
platelets and hematocrit were contemporaneously determined.  
Results: In the perioperative patient population mean FBG concentration was elevated at 5.2 
g/L and mean F XIII concentration was low at 62%. The addition of F XIII led to a FBG 
concentration dependant increase in MCF both in FIBTEM and EXTEM. Mean increases in 
MCF (F XIII vs. DC) of approximately 7 mm and 6 mm were observed in FIBTEM and 
EXTEM, respectively. F XIII addition also led to decreased CFT, increased αA, and reduced 
ML in FIBTEM and EXTEM. 
Conclusions: In vitro supplementation of F XIII to supraphysiologic levels increases 
maximum clot firmness, accelerates clot formation and increases clot stability in EXTEM and 
FIBTEM as assayed by ROTEM® in perioperative patients with high fibrinogen and low F 
XIII levels. 
Words: 249 
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Introduction 
Blood coagulation factor XIII (F XIII) is a protransglutaminase that is present in plasma, 
platelets, monocytes and monocyte-derived macrophages. It becomes activated by the 
combined action of thrombin and Ca2+ in the final phase of the clotting cascade. Plasma F 
XIII circulates in association with its substrate precursor, fibrinogen, which has an important 
regulatory impact in the activation of plasma F XIII [1, 2]. Relevant physiologic functions of 
F XIII include cross-linking of fibrin monomers amongst themselves to generate a stable 
fibrin strand, cross-linking fibrinogen with α2 antiplasmin, a potent plasmin inhibitor, to 
protect the fibrin clot from fibrinolysis, and cross-linking the fibrin clot with subendothelial 
collagen and fibronectin resulting in clot localization at a site of injury [3, 4]. While 
Fibrinogen is an acute phase protein whose concentration increases in relation to the extent of 
the acute phase reaction, F XIII is not up-regulated under the same circumstances. We thus 
hypothesized that a relative F XIII deficiency might occur in the presence of an acute phase as 
manifested in our patient population. 
 
After severe trauma and in major surgery severe bleeding leads to considerable decrease of all 
coagulation factors. Secondary to its loss as well as its consumption, hemodilution by volume 
replacement therapy additionally reduces the plasma coagulation factor fraction. Like in burn 
patients it is assumed that F XIII concentration may be low following trauma and in major 
surgery and may be responsible for otherwise inexplicable intra- and postoperative bleeding 
[5-7]. F XIII is not detected by routine laboratory screening such as prothrombin time (PT) 
and partial thromboplastin time (PTT). F XIII assays are often only available in specialized 
laboratories. Furthermore, determination of F XIII using plasma-based testing is time 
consuming due to the obligatory prior sample centrifugation. 
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Point of care monitoring of blood coagulation at the patients bed side is becoming 
increasingly relevant and provides real-time results. Detecting F XIII deficiency with point of 
care devices would be desirable. Most recently, Weber and colleagues [8] reported the 
detection of unknown F XIII deficiency by Thromboelastometry in one case. Should 
ROTEM® indeed have the ability to reliably detect the functional consequences of changes in 
F XIII concentrations on clot formation, it might become a point of care device for guiding 
the treatment with F XIII in real time. 
 
The goal of this study was to investigate in-vitro supplementation of F XIII with 0.32 IU F 
XIII, resulting in F XIII concentration of approximately 150 %, 0.63 IU FXIII resulting in F 
XIII concentration of 300 % and 1.25 IU resulting in F XIII concentration of 600 % to see 
whether clot characteristics as assayed by ROTEM® in the EXTEM and FIBTEM tests, both 
of which are fibrinogen and F XIII dependent, are to be improved in patients with laboratory 
proven F XIII deficiency. No comparison of ROTEM® tests after in vivo treatment with F 
XIII was made in the current study, and therefore no direct extrapolation to any clinical 
situation should be made. 
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Materials and Methods 
This study was performed after obtaining authorization by the local ethic committee 
(Kantonale Ethikkommission, Kanton Zürich, Switzerland, Study number StV 27-2007, 
amendment 3). As patients were in a critical and life threatening situation not allowing direct 
written informed consent, consent was obtained by signed consent form by exception [9]. 
Inclusion criteria were: Patients needing ROTEM® measurements postoperatively because of 
a presumed coagulation problem and F XIII, platelets and fibrinogen being determined by the 
institutional laboratory. Exclusion criteria were: known coagulopathic disorders and 
thrombocytopenia  100 000/μl. 
Ninety critical care patients were enrolled consecutively after major surgery in pre-specified 
order in this prospective single-center trial and each 30 patients were allocated to one of three 
ROTEM® groups, respectively. Enrollment occurred within six hours after major surgery. 
The ROTEM groups were defined by the F XIII added to the ROTEM® tests (0.32 IU in 5 µl, 
0.63 in 10 µl or 1.25 IU in 20 µl). In the intensive care unit (ICU) two samples of citrated and 
one sample of EDTA whole blood were collected in each patient, contemporaneously. Platelet 
count was determined in the EDTA sample and fibrinogen and F XIII concentrations were 
determined in one of the two citrated blood samples of each patient by the institutional 
laboratory. The second citrated whole blood sample was used for EXTEM and FIBTEM 
measurements i) after addition of 0.32, 0.63 and 1.25 IU of F XIII in a volume of 5, 10 and 
20μl, ii) after addition of 5, 10 and 20 μl of aqua injectabile (diluent controls, DC) and iii) 
without addition of any further reagent (baseline measurements).  
ROTEM® tests were performed according to the manufacturer’s instructions at 37° C and ran 
for 62 minutes using two ROTEM® devices simultaneously. To optimize comparability, F 
XIII-supplemented samples and diluent control samples were run on the same machine, while 
baseline samples were measured in parallel on the second machine.  
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 Parameters of Rotation Thromboelastometry: ROTEM® assesses the kinetics and quality 
of clot formation and clot lysis in real-time. The clotting time (CT) is defined as the period of 
time from the start of the analysis until the start of clot formation, normally until the 2 mm 
amplitude is reached. The clot formation time (CFT) is defined as the period until the 20 mm 
amplitude is reached. The α-angle (αA) is defined as the angle between the centre line and a 
tangent to the curve through the 2 mm amplitude point, which is the end of the CT. The 
maximum amplitude of the curve is defined as the maximum clot firmness (MCF). The 
maximum lysis (ML) represents the maximum fibrinolysis detected during the measurement. 
The maximum clot elasticity (MCE) is a calculated parameter from MCF values, and is 
intended to allow a better interpretation of MCF in case of high amplitudes in MCF. Further 
details on that subject haven been recently been published by Theusinger and colleagues. [10] 
For the purpose of this paper we define ΔMCF as being the difference in MCF of a FXIII 
supplemented sample and the related diluent control. The same definition was used for 
ΔMCE. 
The following parameters were collected: Clotting time (CT), Clot formation time (CFT), α-
angle (αA), Maximum clot firmness (MCF), Maximum clot elasticity (MCE) and Maximum 
lysis (ML) for EXTEM. In FIBTEM only CT, MCF, MCE and ML were analyzed. 
 
Test procedure 
The two ROTEM® devices being used in this study were set up by a representative of the 
manufacturer; both devices had been calibrated and tested before the study started. All tests 
were performed according to the instructions of the manufacturer. For each measurement a 
new pin was positioned on the axis of the measurement channel and a new cup was put into 
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the special cup holder of the device. The automated pipette programs was used for baseline 
measures, with 20 µl re-calcification reagent (200 mmol/l calcium chloride solution) and 20 
µl of the respective activation reagent (FIBTEM: cytochalasin D, EXTEM: thromboplastin 
from rabbit brain) were added into the pre-warmed cup. Then 300 µl of citrated whole blood 
was added to the cup and, after a semi-automated mixing step, the cup holder was placed to 
the measuring position of the ROTEM® device. The measurement started automatically when 
blood was added to the cup and stopped after 62 min. (ex-TEM lot 41194401, fib-TEM lot 
41147601, star-TEM lot 41166101) 
For FXIII supplemented tests as for diluent controls, the appropriate volumes of F XIII 
(Fibrogammin P® 250 IU in 4 ml, lot 23164211 J, CSL Behring, Zürich, Switzerland) and 
diluent (aqua injectabile, lot 71511011, CSL Behring GmbH, Marburg, Germany) were added 
to the cup prior to initialization of the pipetting program.  
The laboratory analyses were performed in quality controlled ISO 17025 accredited university 
laboratories. F XIII was determined on Behring Coagulation System (Dade Bering, Düdingen, 
Switzerland) using the Berichrom® F XIII test (Dade Bering, Düdingen, Switzerland; normal 
range 70-140% which equals 0.7-1.4 IU/ml). This test measures the function of F XIII. 
Fibrinogen was also analyzed by the Behring Coagulation System (Dade Bering, Düdingen, 
Switzerland) using the Multifibrin® U test (Dade Bering, Düdingen, Switzerland; normal 
range 1.5 – 4.0 g/l). Platelet count was measured with Advia® 2120 (Siemens Healthcare 
Diagnostics GmbH, Eschborn, Germany; normal range 143 – 400 x109/l).  
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Statistical Analyses 
Data were transferred from the ROTEM® devices into Microsoft Excel (Microsoft Office 
2007, Microsoft Corporation Redmond, WA, US) and analyzed using SPSS® (version 16, 
SPSS Inc. Chicago, Illinois, USA). Continuous variables are summarized as mean ± SD. 
Within each of the three F XIII supplementation groups 0.32, 0.63 and 1.25 IU, values of CT, 
CFT, ML, α-angle, MCE and MCF of EXTEM, and CT, ML, MCE and MCF of FIBTEM 
were compared between different samples (baseline, DC, and F XIII). ANOVA for repeated 
measures with Bonferroni post hoc test was used to analyze these differences. Because of 
expected high fibrinogen concentrations and hence high MCF values particularly in the 
FIBTEM, ΔMCF values for EXTEM and FIBTEM were calculated by subtracting the MCF 
of the diluent control sample from those of the F XIII added sample. Thereafter, the resulting 
ΔMCF values were correlated with the fibrinogen concentration, F XIII concentration and the 
fibrinogen to F XIII ratio (FBG:F XIII ratio) using linear regression and reporting r-square 
values. P-values of 0.05 or less are considered significant. 
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Results 
1. Patient characteristics 
Ninety critically ill patients after cardiac, major vascular and major non cardiac surgery were 
included. Age, sex, BMI, fibrinogen and F XIII concentrations, platelet count and hematocrit 
were not significantly different in the three groups (table 1).  
2. Effects of FXIII supplementation on FIBTEM 
As compared to DC, F XIII addition led to significantly increased mean MCF and 
significantly decreased ML in FIBTEM (table 2). The effect on mean MCF was not 
dependent on F XIII dose (table 2) or basal F XIII concentration (figure 3). The ML of the F 
XIII group was reduced significantly vs. diluent controls also in a non dose dependent 
manner. 
3. Effects of FXIII supplementation on EXTEM 
As shown in table 3, the addition of 0.32, 0.63 and 1.25 IU of F XIII led to a significant 
increase of MCF as compared to diluent control. The effect on mean MCF in the three groups 
(0.32, 0.63 and 1.25 IU) was not dose-dependent. We also observed a significant non dose 
dependent reduction of mean ML for all three groups. 
4. Effects on MCE of F XIII supplementation on EXTEM and FIBTEM 
As MCE is calculated via the MCF values [MCE = (100*MCF)/(100-MCF)] descriptive 
statistic was made and is shown in table 2 and 3. Highly significant (p<0.01) were the changes 
of F XIII compared to DC. MCE increased after addition of F XIII and decrease in the DC 
group. Those results are similar to the MCF changes. 
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5. Correlation of ΔMCF and ΔMCE with determining factors of MCF  
MCF of FIBTEM is determined by the FBG and F XIII concentration. We thus plotted ΔMCF 
vs. FBG concentration (figure 1), ΔMCF vs. F XIII concentration (figure 3) and ΔMCF vs. 
FBG:F XIII ratio (figure 2) for the three groups (0.32, 0.63 and 1.25 IU). Table 4 illustrates 
the mean ΔMCF for FIBTEM and EXTEM measurements. For ΔMCE which is calculated via 
the MCF values, only the correlations of ΔMCE in the 0.32 IU group versus the platelets for 
EXTEM and FIBTEM, were significant (r2 respectively for EXTEM 0.22, p<0.01, and 
FIBTEM 0.19, p<0.05). All other correlations were non-significant. 
ΔMCF increased with increasing FBG concentration. The correlation was positive in all three 
groups with values of r2=0.36 (p<0.01), r2=0.04 (p=0.19), r2=0.55 (p<0.01) in the F XIII 0.32, 
0.63 and 1.25 IU groups, respectively. At low FBG concentration there were no or only small 
ΔMCF irrespective of the dose of F XIII added. At high FBG concentration ΔMCF increased 
proportionately. Accordingly, the slope of the regression is highest for 1.25 IU and lower for 
the other two groups (figure 1). 
ΔMCF did hardly increase with increasing basal F XIII concentration (figure 3). For both the 
0.32 and the 0.63 IU groups the regression curves are nearly horizontal with r2 =0.01(p=0.33 
and p=0.49). In the 1.25 IU group r2 was 0.05 (p=0.67). The correction of the pre-existing 
absolute F XIII deficiency (mean F XIII concentration was 63% for 0.32 IU group, 66% for 
0.63 IU group and 56% for the 1.25 IU group; table 1) led to mean increases in MCF of 4.9, 
8.0 and 8.3 mm respectively (table 4). We also plotted ΔMCF against a parameter known not 
to be associated with MCF in FIBTEM, namely platelet count and found nearly horizontal 
regression lines (data not shown). 
Comparing the ΔMCF of FIBTEM with the ratio of fibrinogen concentration to F XIII 
(FBG:F XIII ratio) showed that the lower the FBG:F XIII ratio, the higher is the effect of 
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added F XIII on FIBTEM (figure 2). These findings were significant (p<0.01) in the 0.32 IU 
(r2=0.22) and the 1.25 IU (r2=0.31) group. 
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Discussion  
Factor XIII (F XIII) is essential for clot stability as assayed by ROTEM® tests. Utilizing an 
in-vitro supplementation model, we investigated the impact of F XIII substitution on EXTEM 
and FIBTEM measurements indicative of clot firmness and stability in 90 critically ill patients 
with high FBG and low F XIII concentrations. The main findings of the current study are that 
in vitro supplementation of F XIII to supraphysiologic levels increases maximum clot 
firmness, accelerate clot formation and increases clot stability in EXTEM and FIBTEM 
postoperative patients. The positive effect of F XIII supplementation on MCF was dependent 
on basal FBG concentration, with higher ΔMCF reached at high FBG concentration. The 
effect was independent of basal F XIII concentration or basal platelet count. The FBG 
concentration dependent effect on MCF suggests a relative F XIII deficiency in states of high 
FBG and concomitantly low F XIII concentrations.  
 
Due to sample preparation and test procedures, current plasma-based tests for F XIII function 
or antigen are time consuming and cumbersome [11] [12]. Furthermore, these tests are 
frequently not readily available or not available on a 24 hour 7 day a week basis. Finally, 
these tests have test-related limitations. Point of care testing using viscoelastic methods can be 
utilized on site in emergency facilities and operating theaters permitting constant and 
immediate availability of analyses around the clock. Ours findings suggest that, in vitro 
monitoring of acquired or inherited F XIII deficiency may be possible using ROTEM®. 
However, since no ROTEM ® test before and after in vivo treatment with F XIII were 
performed, no direct extrapolation to any clinical situation should be made.  
 
F XIII has an impact on thromboelastography and thromboelastometry, which has been 
previously reported by several investigators [13-15]. In an in-vitro and plasma-based study 
using thromboelastography, Nielsen and colleagues [14] have shown that increasing 
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concentrations of F XIII improved clot strength as evidenced by an increased maximum 
amplitude (MA) and alpha angle, and a decreased coagulation time (r). The same investigators 
reported in a subsequent study that exposure of normal plasma to anti-F XIII antibodies 
resulted in a significant decrease in clot strength (63%). In addition, they found that F XIII-
induced cloth strength varied between 44 and 50% in hypercoagulable and hypocoagulable 
plasma, respectively. In the current investigation the MCF of EXTEM and FIBTEM of 
ROTEM® significantly increased by addition of F XIII resulting in final concentrations near 
(150% in the 0.32 IU group) or well above the physiologic range (300 and 600% in the 0.63 
and 1.25 IU group). Additionally the clot formation time of the EXTEM was considerably 
shortened. CFT of EXTEM mainly depends on the activity of platelets and those of F XIII, 
whereas in FIBTEM the platelets are inhibited. More than two thirds and approximately half 
of all critically ill patients included in this study suffered F XIII plasma concentrations < 70% 
and < 60%, respectively.  
 
Recently Weber and colleagues [8] described the detection of F XIII deficiency by ROTEM® 
in a patient undergoing a Whipple's operation. They observed significant maximum lysis in 
both EXTEM and APTEM (in vitro addition of aprotinin) and a reduction in the maximum 
lysis after addition of F XIII in the in EXTEM measure. This patient had an acquired F XIII 
deficiency. In another case report, Dargaud and co-workers reported [16] a patient with 
known mutation of factor V Leiden and severe F XIII deficiency. They observed reduced clot 
strength (MCF) and impaired clot stability (increased maximum lysis) in the baseline 
measurement of ROTEM®. After addition of F XIII an increase in the MCF and a decrease of 
maximum lysis was observed. They concluded that ROTEM® was able to detect viscoelastic 
changes of fibrin clot in whole blood samples with acquired low F XIII activity. MCF thus 
may be a valuable surrogate marker in patients treated with F XIII. These findings [8, 16] 
were confirmed in our investigation. In the same manner, the addition of F XIII increased the 
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MCF in EXTEM and reduced significantly the ML in EXTEM and FIBTEM. EXTEM and 
FIBTEM seem to be sensitive tools to detect the protective and stabilizing effect of F XIII on 
clot strength and the degradation caused by fibrinolysis. These findings are supported by the 
observations, that a reduction of maximum lysis of EXTEM has been reported in patients with 
very low levels of F XIII as well as by the fact that an aprotinin resistant lysis can be 
corrected by F XIII and is an indicator for a F XIII deficiency [14, 17].   
 
The impact of F XIII on clot firmness, as presented in the current study, is in keeping with the 
recently published investigation of Korte and colleagues [18]. They were able to show in 
gastrointestinal cancer patients that substitution of F XIII led to a smaller reduction of MCF in 
EXTEM and a reduction of blood loss, compared a control group of patients with no F XIII 
supplementation. Possible reasons discussed were that either high doses of F XIII given 
reduce the consumption of fibrinogen due to increased clot firmness or that F XIII protects 
fibrinogen from plasmin degradation. 
 
Our current investigation has limitations. One regards F XIII supplementation to 
supraphysiologic levels ranging from 150 (in the 0.32 IU group) to 600% (1.25 IU group). We 
hypothesize that the lack of a F XIII dependent dose response effect is due to this fact. With 
the dose of 0.32 IU the resultant F XIII concentration in the sample was already above the 
physiologic level. It was thus only under the extreme FBG values, where at higher doses of 
FXIII an additional effect on MCF could be observed. Again we interpret these findings to be 
indicative of a relative F XIII deficit. Other limitations include supplementation with various 
volumes (5, 10 and 20 μl). Compared to the total sample volume the relation is small and we 
did perform baseline tests without any supplementation that permit to evaluate the relative 
contribution of sample dilution. The final limitation is that there were no ROTEM ® tests 
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performed before and after in vivo treatment with F XIII and thus no direct extrapolation to 
any clinical situation should be made. 
 
Fibrinogen is an acute phase reactant and thus frequently elevated in the periopertive context. 
In contrast, low F XIII concentrations are prevalent in critically ill patients [18]. This 
constellation of high FBG and low F XIII concentrations or a high FBG:F XIII ratio thus 
appears to be of high prevalence. In all groups, the fibrinogen concentration was elevated and 
F XIII concentration was reduced (table 2). Interestingly, the effect of adding F XIII on 
ΔMCF-FIBTEM did not depend on the F XIII concentration (figure 3). However, the effect of 
adding F XIII was greater at higher fibrinogen concentrations in the 0.32 and 1.25 IU groups 
(figure 1). This may represent a relative F XIII deficiency at high fibrinogen levels. We 
therefore introduced the ratio between fibrinogen and F XIII concentrations (FBG:F XIII 
ratio). The higher the FBG:F XIII ratio the greater was the effect of adding F XIII on ΔMCF-
FIBTEM in the 0.32 and 1.25 IU groups (figure 2). In our in vitro model we observed 
improved clot qualities after F XIII supplementation to supraphysiologic final concentrations. 
Future clinical studies will have to show whether or not the concept of relative F XIII 
deficiency that we describe will prove clinically useful. Placebo-controlled trials comparing F 
XIII substitution according to the ratio of FBG to F XIII concentrations vs. F XIII 
concentration alone will clarify whether the current in vitro observations, will result in a 
clinically relevant benefit to the perioperative patient.  
 
Conclusion: The results of the current investigation suggest that in vitro supplementation of 
high doses F XIII improves clot firmness and stability in EXTEM and FIBTEM as assessed 
by ROTEM® in the case of absolute or relative F XIII deficiency. Further investigations need 
to demonstrate whether supplementation of F XIII to physiological concentrations has a 
similar impact on clot firmness.  
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Figure legends 
 
Figure 1: Regression analysis of ΔMCF-FIBTEM vs. basal FBG for different doses of F XIII 
supplementation (0.32, 0.63, 1.25 IU). 
 
Annotation: ΔMCF-FIBTEM, difference between MCF-FIBTEM with added F XIII and 
MCF-FIBTEM diluent control (DC). (0,32 IU r2=0.36, p<0.01; 0,63 IU r2=0.04, p=0.19; 1.25 
IU r2=0.55, p<0.01) 
 
 
Figure 2: Regression analysis of different doses of F XIII supplementation (0.32, 0.63, 1.25 
IU) between ΔMCF-FIBTEM and ratio FBG:F XIII concentrations. 
 
Annotation: ΔMCF-FIBTEM, difference between MCF-FIBTEM with added F XIII and 
MCF-FIBTEM diluent control (DC); ratio FBG:F XIII (%), concentration of fibrinogen 
divided by F XIII concentration, expressed in a percentage decimal count. (0,32 IU r2=0.22, 
p<0.01; 0,63 IU r2=0.03, p=0.34; 1.25 IU r2=0.31, p<0.01) 
 
 
 
Figure 3: Regression analysis of ΔMCF-FIBTEM vs. basal F XIII for different doses of F 
XIII supplementation (0.32, 0.63, 1.25 IU). 
 
Annotation: ΔMCF-FIBTEM, difference between MCF-FIBTEM with added F XIII and 
MCF-FIBTEM diluent control (DC). (0,32 IU r2=0.01, p=0.33; 0,63 IU r2=0.01, p=0.49; 1.25 
IU r2=0.05, p=0.67) 
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Tables 
 
Table 1 Patient characteristics 
Parameter 0.32 IU group 0.63 IU group 1.25 IU group 
    
Age 62.6±15.5 60.8±16.3 61.4±15.0 
Sex (m/f) 26/4 27/3 23/7 
BMI (kg/m2) 25.5±4.1 26.2±3.1 26.1±3.2 
Fibrinogen (g/L) 5.1±1.9 5.6±2.0 5.0±2.5 
F XIII (%) 63±23 66±24 56±15 
Platelet count (G/L) 198±95 199±99 174±89 
Hematocrit (%) 27.0±2.7 26.2±2.3 26.7±3.1 
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Table 2: FIBTEM data 
 
Sample Group MCF (mm) CT (s) ML (%) MCE 
      
Baseline 0.32 IU 23.9±7.6 64.3±11.3 8.1±4.9 31.2±13.8 
 0.63 IU 28.7±10.1 56.3±11.0 3.3±4.2 43.0±19.6 
 1.25 IU 22.4±13.1 86.1±30.4 2.2±2.8 32.8±27.0 
      
FXIII 0.32 IU 28.0±9.9 ** 62.6±9.5* 0.1±0.6** 40.0±20.2** 
 0.63 IU 36.0±12.3 ** 53.9±9.9* 0.4±1.0** 60.2±37.5** 
 1.25 IU 29.5±17.1 ** 77.9±29.0** 0.1±0.4** 49.4±48.5** 
      
DC 0.32 IU 23.1±8.2 69.6±14.1 2.5±5.2 32.6±13.1 
 0.63 IU 28.2±10.7 60.6±10.1 2.9±4.2 42.3±21.7 
 1.25 IU 21.3±13.3 99.4±34.3 1.9±2.9 31.5±27.6 
 
Significances were addressed DC vs. F XIII: * denotes  p < 0.05; ** denotes p < 0.001 
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Table 3 EXTEM data  
 
Sample Group MCF (mm) CT (s) CFT (s) αA (°) ML (%) MCE 
        
Baseline 0.32 63.2±7.3 65.3±11.6 85.7±43.6 73.5±7.4 8.1±4.9 180.7±54.0 
 0.63 66.0±8.9 57.6±9.2 74.4±37.0 75.5±6.6 5.9±3.8 211.9±74.0 
 1.25 61.3±9.3 96.6±40.9 95.6±36.0 71.5±6.8 5.9±3.8 175.5±75.5 
        
FXIII 0.32 67.3±8.5 ** 63.0±11.4 78.5±42.3 * 75.0±7.0 ** 2.9±1.8** 221.7±72.9**
 0.63 68.9±8.4 ** 54.9±6.4** 66.8±40.5 ** 77.3±7.0 ** 3.0±1.7** 242.6±84.6**
 1.25 64.4±9.9 ** 83.7±29.6 * 90.9±43.9** 72.8±7.9** 2.5±1.4** 206.8±99.3**
        
DC 0.32 61.1±7.9  67.8±9.4 88.4±50.8 73.3±7.8 9.8±3.6 180.7±50.9 
 0.63 64.1±9.8  61.8±9.5 81.1±43.0  74.4±7.3 7.5±7.0 196.2±72.4 
 1.25 58.7±9.5  100.8±37.1 107.7±44.2 69.5±7.7  8.6±5.7 156.9±70.3 
 
 
Significances were addressed DC vs. F XIII: * denotes  p < 0.05; ** denotes p < 0.001.  
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Table 4: ΔMCF data for F XIII vs. DC 
 
Group FIBTEM ΔMCF (mm) EXTEM ΔMCF (mm)  
   
0.32 IU 4.9±2.6 ** 6.0±3.6 ** 
0.63 IU 8.0±6.5 ** 5.0±4.2 ** 
1.25 IU 8.3±6.0 ** 5.6±4.2 ** 
   
Significances were addressed DC vs. F XIII: ** denotes p < 0.001.
Figures 
 
 
Figure 1: Regression analysis of the different doses of F XIII supplementation (0.32, 0.63, 1.25 IU) between ΔMCF-FIBTEM and fibrinogen 
concentrations. 
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Figure 2: Regression analysis of the different doses of F XIII supplementation (0.32, 0.63, 1.25 IU) between ΔMCF-FIBTEM and ratio FBG: F XIII 
concentrations. 
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Figure 3: Regression analysis of the different doses of F XIII supplementation (0.32, 0.63, 1.25 IU) between ΔMCF-FIBTEM and F XIII 
concentrations. 
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